These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7923984)

  • 1. Hemodialysis using high flux membranes improves lipid profiles.
    Blankestijn PJ
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S48-51. PubMed ID: 7923984
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
    Floege J; Koch KM
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term experience with high-flux polysulfone in hemodialysis.
    Civati G; Teatini U; Guastoni C; Perego A; Perrino ML; Ballerini L; Minetti L
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S26-30. PubMed ID: 7923979
    [No Abstract]   [Full Text] [Related]  

  • 4. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of the new, steam-sterilized polysulfone high-flux dialyzer.
    Schaefer RM; Kulzer P; Gilge U; Schaefer L; Heidland A
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S21-5. PubMed ID: 7923978
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphate removal during dialysis--does the membrane matter?
    Ritz E
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S57-60. PubMed ID: 7923986
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased soluble CD14 levels in patients on hemodialysis. Influence of dialysate endotoxin or incompatibility to dialyzer membranes?
    Mitzner S; Stange J; Pichel K; Handschuk I; Korten G; Ehlers M; Schutt C; Schmidt R
    ASAIO J; 1995; 41(3):M707-8. PubMed ID: 8573897
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical experience with polysulfone: 10 years.
    Vanholder R; Van Loo A; Ringoir S
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S13-20. PubMed ID: 7923977
    [No Abstract]   [Full Text] [Related]  

  • 10. All high-flux membranes are equal but some high-flux membranes are less equal than others.
    Vanholder R; Pedrini LA
    Nephrol Dial Transplant; 2008 May; 23(5):1481-3. PubMed ID: 18305315
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
    Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
    Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biocompatibility in long-term hemodialysis: facts--theories--clinical significance].
    Bosch TH; Blumenstein M; Gurland HJ
    Z Urol Nephrol; 1989 Feb; 82(2):69-76. PubMed ID: 2658418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mortality in patients with chronic renal insufficiency undergoing hemodialysis. Hyperlipemia as coadjuvant factor].
    Joven J; Vilella E; Brunzell JD
    Med Clin (Barc); 1991 Jan; 96(3):110-3. PubMed ID: 2033971
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
    Krieter DH; Lemke HD; Wanner C
    Nephrol Dial Transplant; 2006 Feb; 21(2):546; author reply 546. PubMed ID: 16249195
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances and innovations in dialysis in the 21st century.
    Power A; Duncan N; Goodlad C
    Postgrad Med J; 2009 Feb; 85(1000):102-7. PubMed ID: 19329705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The technical evolution of hemodialysis].
    Man NK; Crosnier J
    Ann Med Interne (Paris); 1973 Feb; 124(2):81-4. PubMed ID: 4723745
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of cellulose diacetate dialysis membranes on lipids and lipoproteins in uremic patients].
    Jakić M; Rupcić V; Stipanić S; Samardzija G; Bilandzija M; Zibar L; Mihaljević D; Milas J
    Lijec Vjesn; 1997 Feb; 119(2):56-9. PubMed ID: 9297037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.